Author Archives: William Looney

Pushing the Boundaries of MS Research: The Myelin Repair Foundation

R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
Posted in People, Strategy | Tagged , , , | 2 Comments

HBA's 2014 Woman of the Year: Broadening the Base

HBA’s 2014 Woman of the Year:  Broadening the Base To mark its 25th year in recognizing female leadership in the tough competitive ranks of biopharma, the Healthcare Businesswomen’s Association [HBA] is opting for a breakout triple play.  When the group convenes on May 1 in New York for its annual Woman of the Year [WOTY] […]
Posted in Events, healthcare, leadership, People | Tagged , , , , , | Leave a comment

From Cyprus to Cambridge: The Rise of Anna Protopapas, Millennium Takeda's New President

Takeda’s Oncology Taskmaster Millennium Takeda’s new president, Anna Protopapas, explains to Pharm exec’s William Looney the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease. PE: The ascent to the “c suite” is not exclusively the result of hard work. Culture, […]
Posted in Global, Strategy | Tagged , , , , | Leave a comment

Time for Russia to Get Serious about Biopharma

Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines, still a low-tech purchase, played a modest role in the delivery of health care in both sectors. What happened in the ensuing decades has […]
Posted in Biotech, Emerging Markets, Europe, Global, Strategy | Tagged , , , | 1 Comment

Engage, But Gently: More Top Line Thoughts on 2014

More Top Line Thoughts on 2014:  Engage, but Gently Two weeks in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over […]
Posted in Op-Ed, Strategy | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta